Recently Visited
{{scheme.stockprice}}
{{scheme.chgp}}%
{{scheme.chgp}}%
{{scheme.scoreText}} |
Score {{scheme.score}}
{{scheme.score}}
{{scheme.scoretext}}
{{ scheme.tag }}
Most Searched
{{scheme.stockprice}}
{{scheme.chgp}}%
{{scheme.chgp}}%
{{scheme.scoreText}} |
Score {{scheme.score}}
{{scheme.score}}
{{scheme.scoretext}}
{{ scheme.tag }}
No Matches Found
Search results for {{searchTermHome}}
{{scheme.stockprice}}
{{scheme.chgp}}%
{{scheme.chgp}}%
{{scheme.scoreText}} | Score
{{scheme.score}}
{{scheme.score}}
{{scheme.scoretext}}
{{ scheme.tag }}
No Matches Found
No Matches Found
Intra-Cellular Therapies, Inc.
Who are in the management team of Intra-Cellular Therapies, Inc.?
Loading...
What does Intra-Cellular Therapies, Inc. do?
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on developing small molecule drugs for neuropsychiatric and neurological disorders, with a market cap of approximately $14 billion. As of December 2024, it reported net sales of $199 million and a net loss of $17 million.
How big is Intra-Cellular Therapies, Inc.?
As of Apr 03, Intra-Cellular Therapies, Inc. has a market capitalization of $14.02 billion, with recent net sales of $680.86 million and a net profit of -$74.68 million. As of Dec'24, the company reported shareholder's funds of $1.15 billion and total assets of $1.37 billion.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
![]( "Upgrade & View All Insights")
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Most Read